Director resignation leaves Renatus Tactical (NASDAQ: RTAC) briefly out of Nasdaq governance compliance
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Renatus Tactical Acquisition Corp. I reported the resignation of director Matan Fattal, effective June 5, 2026. He also left the Audit, Compensation, and Nominating and Corporate Governance Committees, and his departure was stated not to arise from any dispute with the company or its Board.
The resignation leaves the Audit Committee with fewer than three members and the Board without a majority of independent directors, putting the company out of compliance with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b). Renatus has notified Nasdaq, plans to use the applicable cure periods, and is searching for a new independent director to restore compliance.
Positive
- None.
Negative
- Nasdaq governance noncompliance disclosed: After director Matan Fattal’s resignation, Renatus Tactical Acquisition Corp. I no longer has three Audit Committee members or a majority of independent directors, putting it out of compliance with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b) until a new independent director is appointed within the cure periods.
Insights
Director resignation triggers temporary Nasdaq governance noncompliance but cure paths exist.
Renatus Tactical Acquisition Corp. I disclosed that director Matan Fattal resigned from the Board and all committees on June 5, 2026. The company emphasizes his resignation was not due to any dispute over operations, policies, or practices, framing this as a non-conflict departure.
This exit leaves the Audit Committee with fewer than three members and removes the Board’s majority of independent directors, conflicting with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b). The company has informed Nasdaq and intends to rely on cure periods under Rules 5605(c)(4)(B) and 5605(b)(1)(A) while it searches for a new independent director.
For investors, the key issue is whether Renatus can appoint an independent director within the cure windows to restore both Board and Audit Committee independence. Subsequent company disclosures will show if and when a replacement director joins and compliance with Nasdaq listing standards is regained.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Warrant exercise price: $11.50 per share
Class A par value: $0.0001 per share
Board composition post-resignation: 2 independent, 2 non-independent, 1 vacancy
+3 more
6 metrics
Warrant exercise price
$11.50 per share
Each whole warrant exercisable for one Class A ordinary share
Class A par value
$0.0001 per share
Par value of Class A ordinary shares in listed units
Board composition post-resignation
2 independent, 2 non-independent, 1 vacancy
Board structure after June 5, 2026 resignation
Audit Committee minimum size rule
3 members required
Nasdaq Listing Rule 5605(c)(2)(A) audit committee requirement
Listing rules cited
5605(c)(2)(A), 5605(b), 5605(c)(4)(B), 5605(b)(1)(A)
Nasdaq governance and cure period provisions referenced
Resignation effective date
June 5, 2026
Effective date of director and committee resignations
Key Terms
Nasdaq Listing Rule 5605(c)(2)(A), independent directors, Audit Committee, Nominating and Corporate Governance Committee, +2 more
6 terms
Nasdaq Listing Rule 5605(c)(2)(A) regulatory
"the Company would no longer continue to satisfy the requirements of Nasdaq Listing Rule 5605(c)(2)(A)"
independent directors financial
"because there is no longer a majority of independent directors on the Board"
Members of a company’s board who do not have significant business, family, or financial ties to the company and are not part of its management; they are chosen to provide impartial oversight of strategy, financial reporting, executive pay and risk. They matter to investors because independent directors act like an objective referee, helping ensure decisions favor shareholders’ long-term interests rather than insiders, which can strengthen trust and reduce the chance of mismanagement or conflicts of interest.
Audit Committee financial
"resign as a director of the Company and as a member of the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee financial
"member of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
cure periods regulatory
"intends to rely upon the cure periods provided by Nasdaq Listing Rule 5605(c)(4)(B) and 5605(b)(1)(A)"
FAQ
What did Renatus Tactical Acquisition Corp. I (RTAC) announce in this 8-K?
Renatus Tactical Acquisition Corp. I disclosed that director Matan Fattal resigned from the Board and all its committees effective June 5, 2026. The company stated his resignation was not due to any dispute over its operations, policies, or practices with the Board or management.
Why is Renatus Tactical Acquisition Corp. I currently out of compliance with Nasdaq rules?
Following Matan Fattal’s resignation, Renatus Tactical Acquisition Corp. I’s Audit Committee has fewer than three members and the Board no longer has a majority of independent directors. This causes temporary noncompliance with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b) on audit committee and board composition.
How is the Board of Renatus Tactical Acquisition Corp. I composed after the resignation?
After Matan Fattal’s departure, the Board of Renatus Tactical Acquisition Corp. I consists of two independent directors, two non-independent directors, and one vacant seat. The vacant seat is intended to be filled by a new independent director to restore Nasdaq governance compliance.
What steps is Renatus Tactical Acquisition Corp. I taking to regain Nasdaq compliance?
Renatus Tactical Acquisition Corp. I has notified Nasdaq of its temporary noncompliance and plans to rely on cure periods under Nasdaq Listing Rules 5605(c)(4)(B) and 5605(b)(1)(A). The company is actively searching for an independent director to join the Board and Audit Committee.
Did Matan Fattal resign from Renatus Tactical Acquisition Corp. I due to a disagreement?
The company stated that Matan Fattal’s resignation from the Board and its committees was not the result of any dispute or disagreement with Renatus Tactical Acquisition Corp. I or its Board regarding operations, policies, or practices, indicating a non-contentious departure.
What securities of Renatus Tactical Acquisition Corp. I are listed on Nasdaq and under which symbols?
Renatus Tactical Acquisition Corp. I has units, Class A ordinary shares, and warrants listed on the Nasdaq Global Market. The units trade under RTACU, the Class A ordinary shares under RTAC, and the warrants under RTACW, each tied to its SPAC structure.